Biologically active peptides play a significant part in human health. They are linked to the development of novel therapeutic healthcare products, as well as possible biological pathway markers and metabolites for disease detection.
Hamilton selected peptides of increasing amino acid length to emphasize the effectiveness of the PRP-3 (300 Å) HPLC stationary phase in peptide research.
Evaluation of the stationary phase suggests a good separation between Angiotensin I and II biomarkers while offering further baseline resolution between the analytes that remain. The chromatogram also displays the peak shape and resolution an analyst can anticipate while using the PRP-3 stationary phase. In this example, Hamilton selected the 7 μm particle due to its minimal system back pressure (550 psi) providing the necessary resolution for isolation in an analytical analysis and a scale-up process.
The PRP-3 is the ideal accompaniment for any peptide isolation. The 300 Å particle pore size assists in optimizing the interaction between larger molecular weight peptides and the stationary phase while reducing pores that have been clogged.
Once analytical isolation is accomplished, the PRP-3 shines in scale-up owing to its capacity to accommodate ~20 % additional sample loading prior to observing column overload, compared with non- and superficially porous stationary phases.
Loading capacity is also optimized because of the lack of analyte absorption sites typically observed in silica ODS stationary phases like acidic silanol groups. In spite of not having a silica core, the PRP-3 PSDVB particle offers the consistency and high quality that customers now anticipate from all Hamilton products.
Chromatogram and compound results
Source: Hamilton Company
| Column Information |
| Packing Material |
PRP-3, 7 µm |
| Dimensions |
150 x 4.1 mm |
| P/N |
79466 |
| Chromatographic Conditions |
| Gradient |
0.0 – 20.00 min. 0 – 50 %B |
| Temperature |
30 °C |
| Injection Volume |
5 µL |
| Detection |
UV at 215 nm |
| Eluent A |
H2O + 0.1% TFA |
| Eluent B |
CH3CN + 0.09% TFA |
| Flow Rate |
1.0 mL/min |
Compounds:
- Angiotensin II
- Angiotensin I
- Substance P
- Renin Substrate
- Insulin Chain B
- Melittin
Image Credit: Hamilton Company
About Hamilton Company
Hamilton — The Measure of Excellence
Hamilton Company specializes in the development, manufacturing and customization of precision measurement devices, automated liquid handling workstations, and sample management systems. Hamilton's processes are optimized for quality and flexibility. Whether it's a custom needle with a quick delivery time frame, a special length pH sensor, or a comprehensive solution to fully automate your assay workflow, trust that Hamilton products will always meet your needs.
Hamilton Company has been a leading global manufacturer for more than 60 years, with headquarters in Reno, Nevada; Franklin, Massachusetts; Timișoara, Romania; Bonaduz, Switzerland; and subsidiary offices throughout the world.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.